Improving Outcomes in Diabetes: Focus on SGLT2 Inhibitors. A Medical Experts Discussion
Published: 01 April 2021
This programme has been created with a view to educate primary care healthcare professionals in the UK to understand when, and for whom, they should prescribe SGLT2 inhibitors and to understand the latest advancements in this drug class.
Boehringer Ingelheim Ltd has supported this event as a Medical Education Grant and has had no other involvement in the organisation or the delivery of this programme.
Key Learning Objectives
- Describe how and when to prescribe SGLT2 inhibitors
- Identify patients who are suitable for SGLT2 inhibitors
- Provide appropriate patient education and advice when initiating SGLT2 inhibitors
- Recall the patient populations in whom SGLT2 inhibitors have proven efficacy and safety
- Dr Jas Gill - GP with Special Interest in Cardiology
- Dr Andrew Frankel - Consultant Nephrologist
- Dr Derek Connolly - Consultant Interventional Cardiologist
- Su Down - Nurse Consultant in Diabetes
More from this programme
Welcome and Introductions
Dr Andrew Frankel has been working as a consultant nephrologist at Imperial College Healthcare NHS trust since 1995. He has experience in managing all aspects of kidney disease but has a particular interest in relation to the management of diabetes in the context of kidney disease. Over the years he has maintained a significant research interest in relation to diabetes and kidney, both in terms of how diabetes affects the kidneys leading to deterioration in kidney function, but also in relation to how the presence of kidney disease influences the management of diabetes. Because of this experience, Dr Frankel has played a significant role in the development of national guidelines on the management of diabetes in the context of kidney disease. He is a regular speaker both locally and nationally and indeed internationally in relation to matters pertaining to diabetes and the kidney.
In collaboration with…